The Hans-Guido Wendel Lab: Publications

Share
Print
Share
Print

View a full listing of Hans-Guido Wendel’s journal articles.


The Oncogenic Action of NRF2 Depends on De-glycation by Fructosamine-3-Kinase. 
Sanghvi VR, Leibold J, Mina M, Mohan P, Berishaj M, Li Z, Miele MM, Lailler N, Zhao C, Elisade E, Viale A, Akkari L, Lowe SW, Ciriello G, Hendrickson R, Wendel HG. 2019 August 8. doi: 10.1016/j.cell.2019.07.031.

c-MYC regulates mRNA translation efficiency and start-site selection in lymphoma. Journal of Experimental Medicine. Singh K, Lin J, Zhong Y, Burčul A, Mohan P, Jiang M, Sun L, Yong-Gonzalez V, Viale A, Cross JR, Hendrickson R, Rätsch G, Ouyang Z, Wendel HG. 2019 May 29. doi: 10.1084/jem.20181726.

Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma. Oricchio E, Katanayeva N, Donaldson MC, Sungalee S, Pasion JP, Béguelin W, Battistello E, Sanghvi VR, Jiang M, Jiang Y, Teater M, Parmigiani A, Budanov AV, Chan FC, Shah SP, Kridel R, Melnick AM, Ciriello G, Wendel HG. Sci Transl Med. 2017 Jun 28;9(396). pii: eaak9969. doi: 10.1126/scitranslmed.aak9969. PMID: 28659443

CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. Jiang Y, Ortega-Molina A, Geng H, Ying HY, Hatzi K, Parsa S, McNally D, Wang L, Doane AS, Agirre X, Teater M, Meydan C, Li Z, Poloway D, Wang S, Ennishi D, Scott DW, Stengel KR, Kranz JE, Holson E, Sharma S, Young JW, Chu CS, Roeder RG, Shaknovich R, Hiebert SW, Gascoyne RD, Tam W, Elemento O, Wendel HG, Melnick AM. Cancer Discov. 2017 Jan;7(1):38-53. doi: 10.1158/2159-8290.CD-16-0975. Epub 2016 Oct 12. PMID: 27733359

Characterization of a set of tumor suppressor microRNAs in T cell acute lymphoblastic leukemia. Sanghvi VR, Mavrakis KJ, Van der Meulen J, Boice M, Wolfe AL, Carty M, Mohan P, Rondou P, Socci ND, Benoit Y, Taghon T, Van Vlierberghe P, Leslie CS, Speleman F, Wendel HG. Sci Signal. 2014 Nov 18;7(352):ra111. doi: 10.1126/scisignal.2005500. PMID: 25406379

A cell engineering strategy to enhance the safety of stem cell therapies. Oricchio E, Papapetrou EP, Lafaille F, Ganat YM, Kriks S, Ortega-Molina A, Mark WH, Teruya-Feldstein J, Huse JT, Reuter V, Sadelain M, Studer L, Wendel HG. Cell Rep. 2014 Sep 25;8(6):1677-1685. doi: 10.1016/j.celrep.2014.08.039. Epub 2014 Sep 18. PMID: 25242333

Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy. Oricchio E, Ciriello G, Jiang M, Boice MH, Schatz JH, Heguy A, Viale A, de Stanchina E, Teruya-Feldstein J, Bouska A, McKeithan T, Sander C, Tam W, Seshan VE, Chan WC, Chaganti RS, Wendel HG. J Exp Med. 2014 Jun 30;211(7):1379-91. doi: 10.1084/jem.20132120. Epub 2014 Jun 9. PMID: 24913233